Amarin Corporation PLC (AMRN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amarin Corporation PLC (AMRN) has a cash flow conversion efficiency ratio of 0.014x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($6.39 Million) by net assets ($449.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AMRN equity financing ratio to measure how much of total assets are equity-financed.
Amarin Corporation PLC - Cash Flow Conversion Efficiency Trend (1993–2025)
This chart illustrates how Amarin Corporation PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check AMRN operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Amarin Corporation PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amarin Corporation PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Unggul Indah Cahaya Tbk
JK:UNIC
|
0.088x |
|
Fortune Ng Fung Food Hebei Co Ltd
SHG:600965
|
0.016x |
|
Bermaz Auto Bhd
KLSE:5248
|
0.201x |
|
Southeast Cement Co Ltd
TW:1110
|
0.067x |
|
Nanjing Chixia Development Co Ltd
SHG:600533
|
0.002x |
|
Sichuan Huiyuan Optical Com
SHE:000586
|
0.036x |
|
Lionheart Holdings Unit
NASDAQ:CUBWU
|
-0.001x |
|
Il Dong Pharmaceutical Co Ltd
KO:249420
|
0.050x |
Annual Cash Flow Conversion Efficiency for Amarin Corporation PLC (1993–2025)
The table below shows the annual cash flow conversion efficiency of Amarin Corporation PLC from 1993 to 2025. For the full company profile with market capitalisation and key ratios, see Amarin Corporation PLC (AMRN) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $459.28 Million | $6.74 Million | 0.015x | +123.01% |
| 2024-12-31 | $486.18 Million | $-31.02 Million | -0.064x | -610.03% |
| 2023-12-31 | $552.10 Million | $6.91 Million | 0.013x | +104.14% |
| 2022-12-31 | $595.33 Million | $-179.98 Million | -0.302x | -203.14% |
| 2021-12-31 | $667.10 Million | $-66.53 Million | -0.100x | -187.78% |
| 2020-12-31 | $627.50 Million | $-21.75 Million | -0.035x | -125.06% |
| 2019-12-31 | $608.26 Million | $-9.37 Million | -0.015x | +97.52% |
| 2018-12-31 | $152.33 Million | $-94.70 Million | -0.622x | -223.25% |
| 2017-12-31 | $-65.10 Million | $-32.84 Million | 0.504x | -93.64% |
| 2016-12-31 | $-9.06 Million | $-71.81 Million | 7.928x | +1108.61% |
| 2015-12-31 | $-129.19 Million | $-84.75 Million | 0.656x | -19.76% |
| 2014-12-31 | $-88.45 Million | $-72.31 Million | 0.818x | -85.46% |
| 2013-12-31 | $-33.86 Million | $-190.34 Million | 5.622x | -81.63% |
| 2012-12-31 | $-4.00 Million | $-122.30 Million | 30.599x | +362.56% |
| 2011-12-31 | $-5.96 Million | $-39.44 Million | 6.615x | +3852.38% |
| 2010-12-31 | $-202.37 Million | $-33.87 Million | 0.167x | +128.94% |
| 2009-12-31 | $48.60 Million | $-28.11 Million | -0.578x | +36.67% |
| 2008-12-31 | $28.90 Million | $-26.39 Million | -0.913x | +16.07% |
| 2007-12-31 | $24.15 Million | $-26.28 Million | -1.088x | -79.72% |
| 2006-12-31 | $37.84 Million | $-22.91 Million | -0.605x | -34.98% |
| 2005-12-31 | $38.58 Million | $-17.31 Million | -0.449x | +30.19% |
| 2004-12-31 | $16.69 Million | $-10.73 Million | -0.643x | -119.89% |
| 2003-12-31 | $-6.35 Million | $-20.50 Million | 3.230x | +459.06% |
| 2002-12-31 | $-6.21 Million | $5.59 Million | -0.900x | -257.77% |
| 2001-12-31 | $29.67 Million | $16.91 Million | 0.570x | +216.06% |
| 2000-12-31 | $31.17 Million | $5.62 Million | 0.180x | +123.07% |
| 1999-12-31 | $12.18 Million | $-9.53 Million | -0.782x | -270.26% |
| 1998-12-31 | $-13.50 Million | $-6.20 Million | 0.459x | +1787.78% |
| 1997-12-31 | $14.70 Million | $-400.00K | -0.027x | +94.80% |
| 1996-12-31 | $23.30 Million | $-12.20 Million | -0.524x | -415.25% |
| 1995-12-31 | $28.90 Million | $4.80 Million | 0.166x | +179.99% |
| 1993-12-31 | $18.30 Million | $-3.80 Million | -0.208x | -- |
About Amarin Corporation PLC
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The compa… Read more